FOXM1 and acute myeloid leukemia: The findings of this study on solid cancers are consistent with our recent report in AML [37], which confirms that STL001-induced FOXM1 suppression could be a good therapeutic strategy to overcome drug resistance in both solid tumors and hematological malignancies such as AML.